Back to top

Analyst Blog

Supernus Pharmaceuticals, Inc. (SUPN - Snapshot Report) recently received final U.S. Food & Drug Administration (FDA) approval for Trokendi XR for the treatment of epilepsy.

Trokendi XR is a novel once-daily extended release formulation of Johnson & Johnson's (JNJ - Analyst Report) Topamax (topiramate). This epilepsy product will be launched in a few weeks.

Along with granting approval, the FDA also agreed to a deferral of submission of post-marketing pediatric pharmacokinetic assessments, which were due in 2019, followed by clinical assessments in 2025. Supernus also got an FDA waiver for certain pediatric study requirements.

In Jun 2013, Supernus had received tentative approval for Trokendi XR. Trokendi XR had initially received tentative FDA approval in Jun 2012. However, at that time, the FDA had said that final approval depended on the resolution of a marketing exclusivity issue raised by the FDA regarding a specific pediatric population.

A request for final approval was filed in Dec 2012 along with a safety data update, a new package insert and packaging configurations for Trokendi XR. The FDA had informed Supernus that they will most likely grant this request in the form of a tentative approval because the review period would be expected to conclude within the second quarter, prior to the Jun 22, 2013 expiration of Topamax’ pediatric exclusivity. 

Supernus has another epilepsy product, Oxtellar XR, in its portfolio. Oxtellar XR was launched in the U.S. in Feb 2013. Oxtellar XR was granted three years of marketing exclusivity by the FDA. The company reported meaningful growth in the Oxtellar XR prescriber base in the second quarter of 2013, totaling 3,648, up from 529 in the first quarter. Since its launch, more than 1,100 target physicians have prescribed Oxtellar XR.

Supernus carries a Zacks Rank #2 (Buy). Currently, companies like Questcor Pharmaceuticals Inc. and Actelion Ltd. (ALIOF) look well placed with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CITI TRENDS… CTRN 21.53 +5.49%
GTT COMMUNI… GTT 11.65 +4.11%
ALLERGAN IN… AGN 161.82 +3.99%
WILLIAMS(C)… CWEI 117.06 +3.73%
FIRSTSERVIC… FSRV 54.81 +2.62%